Mastodon

Allergolan (Gel, Drops) Instructions for Use

ATC Code

D04AA13 (Dimetindene)

Active Substance

Dimetindene (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Histamine H1-receptor blocker. Antiallergic drug

Pharmacotherapeutic Group

Antiallergic agent – H1-histamine receptor blocker

Pharmacological Action

Histamine H1-receptor blocker, an alkylamine derivative. It has antiallergic, antipruritic, and a slight anticholinergic effect. It also has a pronounced local anesthetic effect. It causes a weakly expressed sedative effect of central origin.

Pharmacokinetics

It is raply and sufficiently completely absorbed after oral administration. Bioavailability is about 70%. Plasma protein binding is 90%. It penetrates well into tissues and passes through the blood-brain barrier. It is metabolized in the liver by hydroxylation and methoxylation. It is excreted in bile and urine ( 90% as a metabolite and 10% unchanged).

With topical application, Dimetindene rapidly penetrates the skin; systemic bioavailability is 10%.

Indications

For oral administration: urticaria, hay fever, vasomotor rhinitis, food and drug allergy, angioedema; as an adjuvant in the treatment of anaphylactic reactions and serum sickness; pruritus from insect bites, eczema, dermatoses of allergic and non-allergic origin, in measles, rubella, chickenpox. Prophylactic hyposensitizing therapy in patients prone to allergic reactions.

For topical application: pruritic skin lesions in dermatoses, urticaria, insect bites, as well as in mild burns.

ICD codes

ICD-10 code Indication
B01 Varicella [chickenpox]
B05 Measles
B06 Rubella [German measles]
J30.0 Vasomotor rhinitis
J30.1 Allergic rhinitis due to pollen
J30.3 Other allergic rhinitis (perennial allergic rhinitis)
L20.8 Other atopic dermatitis (neurodermatitis, eczema)
L23 Allergic contact dermatitis
L24 Irritant contact dermatitis
L28.0 Lichen simplex chronicus (circumscribed neurodermatitis)
L29 Pruritus
L30.0 Nummular eczema
L50.9 Urticaria, unspecified
T78.1 Other adverse food reactions, not elsewhere classified
T78.3 Angioneurotic edema (Quincke's edema)
T80.6 Other serum reactions
T88.7 Unspecified adverse effect of drug or medicament
ICD-11 code Indication
1E90.Z Varicella, unspecified
1F02 Rubella
1F03 Measles
4A85.21 Urticaria or angioedema caused by food
4A85.2Z Food hypersensitivity, unspecified
9A06.70 Atopic eczema of the eyelids
CA08.00 Allergic rhinitis due to pollen
CA08.03 Other allergic rhinitis
CA08.3 Vasomotor rhinitis
EA80.0 Infantile atopic eczema
EA80.1 Childhood atopic eczema
EA80.2 Adult atopic eczema
EA80.Z Atopic eczema, unspecified
EA82 Nummular dermatitis
EA83.00 Lichen simplex of vulva
EA83.01 Lichen simplex of male genital organs
EA83.02 Lichen simplex of perianal area
EA83.0Z Lichen simplex of unspecified location
EA85.20 Atopic hand eczema
EB04 Idiopathic angioedema
EB05 Hives, unspecified type
EC90.Z Itching, unspecified
EK00.Z Allergic contact dermatitis, unspecified
EK02.Z Irritant contact dermatitis, unspecified
NE60 Poisoning by drugs, medicaments or biological substances, not elsewhere classified
NE80.3 Other serum reactions
NF09 Adverse effects, not elsewhere classified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Gel, Drops

Orally. For adults and children over 12 years of age, the recommended daily dose is 3-6 mg, divided into 3 doses. For children aged from 1 month to 12 years, it is prescribed in a daily dose based on 0.1 mg/kg of body weight. The daily dose must be divided into 3 doses.

Topically. Apply to the affected area of skin 2-4 times/day.

In cases of severe itching or widespread skin lesions, simultaneous use of oral forms is recommended.

Adverse Reactions

From the immune system: with oral administration, very rarely – anaphylactoid reactions, including facial edema, pharyngeal edema, rash, muscle spasms, and shortness of breath.

From the nervous system with oral administration – fatigue, drowsiness (especially at the beginning of treatment), nervousness, excitement, muscle spasm; rarely – headache, dizziness, anxiety.

From the digestive system with oral administration, nausea, dry mouth or throat may occur.

Other with oral administration – edema; rarely – skin rash; in isolated cases – disorders of the respiratory system.

With topical application rarely – dryness and burning sensation at the application site, allergic skin reactions.

Contraindications

Hypersensitivity to dimetindene; angle-closure glaucoma, urination disorders (including with prostatic hyperplasia), children under 1 month of age (especially in case of premature birth).

For oral administration: bronchial asthma; first trimester of pregnancy; breastfeeding period.

Use in Pregnancy and Lactation

Oral administration. Dimetindene is contraindicated for oral administration in the first trimester of pregnancy. Use in the second and third trimesters of pregnancy is possible under medical supervision, only if the expected benefit to the mother outweighs the potential risk to the fetus. Use during breastfeeding is contraindicated.

Topical application. Use in the first trimester of pregnancy is possible only after consultation with a doctor. In the second and third trimesters of pregnancy, as well as during breastfeeding, it should not be applied to large areas of the skin, especially in the presence of inflammation or bleeding. Nursing mothers should not apply the product to the nipples of the mammary glands.

Pediatric Use

Oral administration. Contraindicated for use in children under 1 month of age (especially in case of premature birth). In children aged from 1 month to 1 year, the product should be used only as prescribed by a doctor and if there are indications for the use of H1-histamine receptor blockers, and exceeding the recommended doses should be avoided.

Topical application. In children from 1 month to 2 years, Dimetindene is used only after consultation with a doctor.
In infants and young children, the product should not be applied to large areas of the skin (especially with weeping and inflammation).

Geriatric Use

Use in elderly patients is permitted according to indications in recommended doses.

Special Precautions

Oral administration. In children aged from 1 month to 1 year, the product should be used only as prescribed by a doctor and if there are indications for the use of H1-histamine receptor blockers, and exceeding the recommended doses should be avoided.

Effect on ability to drive vehicles and machinery

During treatment, one should not engage in activities requiring increased attention and quick psychomotor reactions.

Topical application. In children from 1 month to 2 years, Dimetindene is used only after consultation with a doctor.
In infants and young children, the product should not be applied to large areas of the skin (especially with weeping and inflammation). In cases of severe itching or extensive skin lesions, Dimetindene should be used only after consultation with a doctor. When applying dimetindene topically to large areas of the skin, sun exposure should be avoided.
It is not effective for itching associated with cholestasis.

Drug Interactions

With simultaneous use with agents that have a depressant effect on the myocardium, it is possible to enhance the effect of the latter.

With simultaneous use with tricyclic antidepressants or anticholinergic agents, the risk of increased intraocular pressure increases.

MAO inhibitors may cause enhancement of the anticholinergic and sedative effects of dimetindene.

With simultaneous use, Dimetindene enhances the effect of anxiolytics, hypnotics.

With simultaneous consumption of ethanol, a slowing of reaction speed is observed.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Erkapharm, JSC (Russia)

Manufactured By

Tula Pharmaceutical Factory, LLC (Russia)

Dosage Form

Bottle OTC Icon Allergolan Gel for external use 0.1%: tube 30 g

Dosage Form, Packaging, and Composition

Gel for external use homogeneous, colorless, transparent or slightly opalescent, practically odorless.

100 g
Dimetindene maleate 0.1 g

Excipients: disodium edetate – 0.05 g, carbomer – 0.9 g, sodium hydroxide – 0.3 g, benzalkonium chloride – 0.005 g, propylene glycol – 15 g, purified water – up to 100 g.

30 g – aluminum tubes lacquered (1) – cardboard packs.

Marketing Authorization Holder

Erkapharm, JSC (Russia)

Manufactured By

Tula Pharmaceutical Factory, LLC (Russia)

Dosage Form

Bottle OTC Icon Allergolan Oral drops 1 mg/ml: 20 ml bottle

Dosage Form, Packaging, and Composition

Oral drops in the form of a colorless, transparent liquid practically without odor.

1 ml
Dimetindene maleate 1 mg

Excipients: sodium phosphate dibasic dodecahydrate – 16 mg, citric acid monohydrate – 5 mg, benzoic acid – 1 mg, disodium edetate – 1 mg, sodium saccharin – 0.5 mg, propylene glycol – 100 mg, purified water – up to 1 ml.

20 ml – dark glass bottles (1) with a dropper – cardboard packs.

TABLE OF CONTENTS